Molecular assay for K-ras

Thursday, 01 January, 2009 | Supplied by: QIAGEN Pty Ltd



Qiagen has launched a test to determine mutations of the K-ras gene, which can better define which metastatic colorectal cancer (CRC) patients will benefit from treatment with epidermal growth factor receptor (EGFR) inhibiting monoclonal antibodies, such as Amgen’s Vectibix (panitumumab) and Imclone/Bristol-Myers Squibb’s Erbitux (cetuximab).

The PyroMark Q24 K-ras Assay-Kit is CE marked for use in second-line treatment of metastatic CRC together with Erbitux of Vectibix. It can detect all major and minor known mutations in the K-ras codons 12, 13 and 61 and also allows the discovery of new mutations.

The assay is based on Pyrosequencing, a technology for short-length, high-resolution sequence analysis and quantification.

Pyrosequencing reads the actual target sequence and is claimed to be able to detect all known and unknown genetic variations in DNA target regions in which mutations occur. It provides built-in quality control, multiplex formats and is suitable for complex starting materials such as fixed tissue.

 

Online: www.qiagen.com
Phone: 03 9840 9800
Related Products

Tecan Rapid EZ DNA-Seq library preparation kit

Tecan's Rapid EZ DNA-Seq library preparation kit is designed to offer PCR-free generation of...

Air Science PCR laminar flow cabinet

The Air Science PCR laminar flow cabinet employs Air Science Multiplex HEPA filtration technology...

Bruker B.I.QUANT-UR 1.1 module for metabolite quantification in urine

Bruker's B.I.QUANT-UR 1.1 module automatically quantifies up to 150 endogenous and...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd